Targeted Screening For C. difficile Upon Hospital Admission Could Potentially Identify Most Colonized Patients

Washington, DC, May 1, 2013 /3BL Media/ – Testing patients with just three risk factors upon hospital admission has potential to identify nearly three out of four asymptomatic carriers of C. difficile, according to a new study published in the May issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

Researchers from Mayo Clinic in Rochester, MN, analyzed stool samples from 320 patients showing no symptoms of C. difficile at hospital admission using a real-time polymerase chain reaction (PCR) assay. Samples from 31 of 320 patients tested positive for C. difficile, resulting in a colonization rate of 9.7 percent. The authors wanted to estimate the reservoir of colonized patients as a source of potential transmission because despite rigorous infection control measures, C. difficile infection was increasing at their institution.

In this study, independent predictors of C. difficile colonization were found to be recent hospitalization, chronic dialysis and corticosteroid use. According to the authors, one or more of the three independent risk factors were present in 155 (48 percent) of study participants, and screening only those with one or more of these factors would have identified 23 C. difficile carriers (74 percent).

“In our population, by targeting those with identified risk factors, we would need to screen approximately half of those patients with anticipated stays longer than 24 hours, to identify three-fourths of those colonized with C. difficile,” said the authors. “This is in the range of previously published screening efficiency rates for MRSA.”

However, the authors also state that these results should be interpreted keeping in mind that only 22 percent of all eligible patients provided stool for C. difficile PCR, and the study population was not representative of all patients admitted to the hospital.

“Our objective was to estimate the burden of asymptomatic C. difficile carriers at admission because that constitutes an important checkpoint where risk factors can be assessed and infection prevention measures instituted,” said the authors. “This is the first study to demonstrate the feasibility of performing C. difficile surveillance on hospitalized patients at admission. The role of asymptomatic carriers in transmitting C. difficile should be studied further, and the utility of PCR-based targeted surveillance to detect asymptomatic carriers should be explored in areas of high endemicity or outbreak settings when other control measures have been exhausted.”

“While more research needs to be conducted on the transmission of C. difficile infection from colonized patients, this study may help institutions with persistently high rates of transmission develop an expanded strategy for targeted C. difficile surveillance,” said APIC 2013 President Patti Grant, RN, BSN, MS, CIC. “The study does not indicate necessity for all healthcare facility implementation, yet provides a step-wise progressive approach to help impede C. difficile activity when considering the overall epidemiologic impact of transmission.”

C. difficile causes infectious diarrhea and is linked to 14,000 American deaths each year, according to the Centers for Disease Control and Prevention. While many types of healthcare-associated infections have declined in recent years, infections from C. difficile have increased. APIC recently issued a new open-access Guide to Preventing C. difficile infections.

# # #

Notes for Editors
“Asymptomatic Clostridium difficile colonization in a tertiary care hospital: Admission prevalence and risk factors,” by Surbhi Leekha, Kimberly C. Aronhalt, Lynne M. Sloan, Robin Patel and Robert Orenstein appears in the American Journal of Infection Control, Volume 41, Issue 5 (May 2013).

Authors:
Surbhi Leekha, MBBS, MPH (Corresponding Author)
Division of Infectious Diseases, Mayo Clinic, Rochester, MN

Kimberly C. Aronhalt, MA, RN
Infection Prevention and Control Unit, Mayo Clinic, Rochester, MN

Lynne B. Sloan, BS
Division of Clinical Microbiology, Mayo Clinic, Rochester, MN

Robin Patel, MD
Division of Clinical Microbiology, Mayo Clinic, Rochester, MN

Robert Orenstein, DO
Division of Infectious Diseases, Mayo Clinic, Rochester, MN

About AJIC: American Journal of Infection Controls
AJIC: American Journal of Infection Control (www.ajicjournal.org) covers key topics and issues in infection control and epidemiology. Infection preventionists, including physicians, nurses, and epidemiologists, rely on AJIC for peer-reviewed articles covering clinical topics as well as original research. As the official publication of APIC, AJIC is the foremost resource on infection control, epidemiology, infectious diseases, quality management, occupational health, and disease prevention. AJIC also publishes infection control guidelines from APIC and the CDC. Published by Elsevier, AJIC is included in MEDLINE and CINAHL.

About APIC
APIC’s mission is to create a safer world through prevention of infection. The association’s more than 14,000 members direct infection prevention programs that save lives and improve the bottom line for hospitals and other healthcare facilities. APIC advances its mission through patient safety, implementation science, competencies and certification, advocacy, and data standardization. Visit APIC online at www.apic.org. Follow APIC on Twitter: http://twitter.com/apic.   

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact
Liz Garman
+1 202 454 2604
egarman@apic.org